The feasibility of medical control of and prevention of uterine @entity548 secondary to @entity1503 by the induction of prolonged @entity2588 with @entity230 was investigated. 29 @entity1 were treated during a 30-month period. Mean age was 25.7 years and mean parity was 1.8. @entity697 and @entity3039 were the most frequently primary diseases. @entity102 , @entity740 , and @entity2150 were also diagnosed. In 23 @entity1 @entity931 had an unfavorable effect on the primary illness and in 14 it was present when treatment began. All platelet counts were very low. 3 drug regimens were used: 1) @entity8472 + @entity8473 , 2) @entity11796 ( @entity12135 ), and 3) @entity12135 + conjugated @entity172 . Significant @entity1867 occurred in 7 @entity1 (24%) and was not related to the degree of @entity882 . Average length of treatment was 15.3 weeks. During the study 18 @entity1 died of their @entity66 . Treatment was discontinued in 7 because of improvement in the @entity66 . In 4 treatment is being continued. As @entity12135 is released slowly, in 10 urgent cases iv conjugated @entity172 were given until @entity548 was controlled or @entity11796 was given orally for a few days. Results show the feasibility of this method of producing therapeutic @entity2588 in the management of a variety of @entity1503 . Fluid retention was more frequent with high @entity172 dosage.

Therapeutic XXXX in @entity1503 .

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogens', 'estrogen'] @entity697 :: ('MESH:D000208', 'Disease') :: ['Acute lukemia'] @entity11796 :: ('MESH:D017258', 'Chemical') :: ['medroxyprogesterone acetate', 'depomedroxyprogesterone acetate'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity66 :: ('MESH:D004194', 'Disease') :: ['primary disease'] @entity2150 :: ('MESH:D000741', 'Disease') :: ['aplastic anemia'] @entity102 :: ('MESH:D002908', 'Disease') :: ['Chronic lukemia'] @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic renal disease'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematologic disease', 'hematologic diseases'] @entity8473 :: ('MESH:D008656', 'Chemical') :: ['mestranol'] @entity8472 :: ('MESH:D009641', 'Chemical') :: ['norethynodrel'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity3039 :: ('MESH:D016553', 'Disease') :: ['immune thrombocytopenic purpura'] @entity931 :: ('MESH:D008595', 'Disease') :: ['menorrhagia'] @entity12135 :: ('MESH:C050795', 'Chemical') :: ['DMPA'] @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea'] @entity1867 :: ('MESH:D008796', 'Disease') :: ['breakthrough bleeding']
@entity2588 :: (MESH:D000568,Disease) :: ['amenorrhea']
